Cargando…

Multilevel modeling and value of information in clinical trial decision support

BACKGROUND: Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women’s Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yuanyuan, Murphy, Brendan, Gentilcore, Anastasia, Sharma, Yugal, Minasian, Lori M, Kramer, Barnett S, Coates, Paul M, Gohagan, John K, Klenk, Juergen, Tidor, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304628/
https://www.ncbi.nlm.nih.gov/pubmed/25540094
http://dx.doi.org/10.1186/s12918-014-0140-0
_version_ 1782354140019556352
author Cui, Yuanyuan
Murphy, Brendan
Gentilcore, Anastasia
Sharma, Yugal
Minasian, Lori M
Kramer, Barnett S
Coates, Paul M
Gohagan, John K
Klenk, Juergen
Tidor, Bruce
author_facet Cui, Yuanyuan
Murphy, Brendan
Gentilcore, Anastasia
Sharma, Yugal
Minasian, Lori M
Kramer, Barnett S
Coates, Paul M
Gohagan, John K
Klenk, Juergen
Tidor, Bruce
author_sort Cui, Yuanyuan
collection PubMed
description BACKGROUND: Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women’s Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial identified the first successful lung cancer screening tool and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial overturned decades-long assumptions. While some trials identify unforeseen safety issues or harms, many fail to demonstrate efficacy. Large trials require substantial resources; to ensure reliable outcomes, we must seek ways to improve the predictive information used as the basis of trials. RESULTS: Here we demonstrate a modeling framework for linking knowledge of underlying biological mechanism to evaluate the expectation of trial outcomes. Key features include the ability to propagate uncertainty in biological mechanism to uncertainty in trial outcome and mechanisms for identifying knowledge gaps most responsible for unexpected outcomes. The framework was used to model the effect of selenium supplementation for prostate cancer prevention and parallels the Selenium and Vitamin E Cancer Prevention Trial that showed no efficacy despite suggestive data from secondary endpoints in the Nutritional Prevention of Cancer trial and found increased incidence of high-grade prostate cancer in certain subgroups. CONCLUSION: Using machine learning methods, we identified the parameters of the model that are most predictive of trial outcome and found that the top four are directly related to the rates of reactions producing methylselenol and transporting extracellular selenium into the cell as selenide. This modeling process demonstrates how the approach can be used in advance of a large clinical trial to identify the best targets for conducting further research to reduce the uncertainty in the trial outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12918-014-0140-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4304628
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43046282015-01-24 Multilevel modeling and value of information in clinical trial decision support Cui, Yuanyuan Murphy, Brendan Gentilcore, Anastasia Sharma, Yugal Minasian, Lori M Kramer, Barnett S Coates, Paul M Gohagan, John K Klenk, Juergen Tidor, Bruce BMC Syst Biol Methodology Article BACKGROUND: Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women’s Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial identified the first successful lung cancer screening tool and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial overturned decades-long assumptions. While some trials identify unforeseen safety issues or harms, many fail to demonstrate efficacy. Large trials require substantial resources; to ensure reliable outcomes, we must seek ways to improve the predictive information used as the basis of trials. RESULTS: Here we demonstrate a modeling framework for linking knowledge of underlying biological mechanism to evaluate the expectation of trial outcomes. Key features include the ability to propagate uncertainty in biological mechanism to uncertainty in trial outcome and mechanisms for identifying knowledge gaps most responsible for unexpected outcomes. The framework was used to model the effect of selenium supplementation for prostate cancer prevention and parallels the Selenium and Vitamin E Cancer Prevention Trial that showed no efficacy despite suggestive data from secondary endpoints in the Nutritional Prevention of Cancer trial and found increased incidence of high-grade prostate cancer in certain subgroups. CONCLUSION: Using machine learning methods, we identified the parameters of the model that are most predictive of trial outcome and found that the top four are directly related to the rates of reactions producing methylselenol and transporting extracellular selenium into the cell as selenide. This modeling process demonstrates how the approach can be used in advance of a large clinical trial to identify the best targets for conducting further research to reduce the uncertainty in the trial outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12918-014-0140-0) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-24 /pmc/articles/PMC4304628/ /pubmed/25540094 http://dx.doi.org/10.1186/s12918-014-0140-0 Text en © Cui et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology Article
Cui, Yuanyuan
Murphy, Brendan
Gentilcore, Anastasia
Sharma, Yugal
Minasian, Lori M
Kramer, Barnett S
Coates, Paul M
Gohagan, John K
Klenk, Juergen
Tidor, Bruce
Multilevel modeling and value of information in clinical trial decision support
title Multilevel modeling and value of information in clinical trial decision support
title_full Multilevel modeling and value of information in clinical trial decision support
title_fullStr Multilevel modeling and value of information in clinical trial decision support
title_full_unstemmed Multilevel modeling and value of information in clinical trial decision support
title_short Multilevel modeling and value of information in clinical trial decision support
title_sort multilevel modeling and value of information in clinical trial decision support
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304628/
https://www.ncbi.nlm.nih.gov/pubmed/25540094
http://dx.doi.org/10.1186/s12918-014-0140-0
work_keys_str_mv AT cuiyuanyuan multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT murphybrendan multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT gentilcoreanastasia multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT sharmayugal multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT minasianlorim multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT kramerbarnetts multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT coatespaulm multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT gohaganjohnk multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT klenkjuergen multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport
AT tidorbruce multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport